PD-1与VEGFR-2双阻断促进肝细胞癌血管正常化并增强抗肿瘤免疫应答
研究利用原位移植或诱导的小鼠肝细胞癌模型重现临床结局:抗VEGFR-2抗体单药显著延缓原发肿瘤生长但未延长生存,抗PD-1单药在一模型中仅获轻微生存优势,而双抗PD-1/VEGFR-2治疗显著抑制原发肿瘤生长并使两模型生存期翻倍。联合治疗通过增加CD8+细胞毒性T细胞浸润与活化、改变肿瘤相关巨噬细胞M1/M2比值、减少Treg及CCR2+单核细胞浸润重塑免疫微环境。
要点
- 双抗PD-1/VEGFR-2治疗在原位移植及诱导小鼠HCC模型中显著抑制原发肿瘤生长并使生存期翻倍。
- 联合治疗增加CD8+细胞毒性T细胞浸润与活化,改变M1/M2比值,减少Treg和CCR2+单核细胞浸润。
- 抗VEGFR-2阻断内皮细胞可旁分泌诱导HCC细胞PD-L1表达,部分通过干扰素-γ;VEGFR-2阻断还增加肿瘤浸润CD4+细胞PD-1表达。
核心结论
- 双抗PD-1/VEGFR-2治疗在HCC中具有持久的血管加固效应,可克服对任一单药治疗的耐药,并在抗PD-1治疗耐药和敏感HCC模型中均提高总生存期。
研究设计与样本
- 研究采用原位移植或诱导的小鼠肝细胞癌模型,使用鼠源抗体特异性阻断VEGFR-2及抗PD-1抗体治疗。
主要发现
- 抗VEGFR-2抗体单药显著延缓原发肿瘤生长但未能延长生存;抗PD-1抗体单药在一模型中仅获轻微生存优势。
- 双抗PD-1/VEGFR-2治疗显著抑制原发肿瘤生长,并在两个模型中使生存期翻倍。
- 联合治疗增加CD8+细胞毒性T细胞浸润与活化,改变肿瘤相关巨噬细胞M1/M2比值,减少Treg和CCR2+单核细胞浸润。
- VEGFR-2选择性表达于肿瘤内皮细胞;抗VEGFR-2阻断内皮细胞后,部分通过干扰素-γ以旁分泌方式诱导HCC细胞PD-L1表达。
- VEGFR-2阻断增加肿瘤浸润CD4+细胞PD-1表达;抗PD-1治疗下CD4+细胞在抗VEGFR-2抗体抗血管生成治疗中促进正常化血管形成。
临床怎么用
- 原文未提供临床实践推荐。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Activation of the antitumor immune response using programmed death receptor-1 (PD-1) blockade showed benefit only in a fraction of patients with hepatocellular carcinoma (HCC). Combining PD-1 blockade with antiangiogenesis has shown promise in substantially increasing the fraction of patients with HCC who respond to treatment, but the mechanism of this interaction is unknown. APPROACH AND RESULTS: We recapitulated these clinical outcomes using orthotopic-grafted or induced-murine models of HCC. Specific blockade of vascular endothelial receptor 2 (VEGFR-2) using a murine antibody significantly delayed primary tumor growth but failed to prolong survival, while anti-PD-1 antibody treatment alone conferred a minor survival advantage in one model. However, dual anti-PD-1/VEGFR-2 therapy significantly inhibited primary tumor growth and doubled survival in both models. Combination therapy reprogrammed the immune microenvironment by increasing cluster of differentiation 8-positive (CD8+ ) cytotoxic T cell infiltration and activation, shifting the M1/M2 ratio of tumor-associated macrophages and reducing T regulatory cell (Treg) and chemokine (C-C motif) receptor 2-positive monocyte infiltration in HCC tissue. In these models, VEGFR-2 was selectively expressed in tumor endothelial cells. Using spheroid cultures of HCC tissue, we found that PD-ligand 1 expression in HCC cells was induced in a paracrine manner upon anti-VEGFR-2 blockade in endothelial cells in part through interferon-gamma expression. Moreover, we found that VEGFR-2 blockade increased PD-1 expression in tumor-infiltrating CD4+ cells. We also found that under anti-PD-1 therapy, CD4+ cells promote normalized vessel formation in the face of antiangiogenic therapy with anti-VEGFR-2 antibody. CONCLUSIONS: We show that dual anti-PD-1/VEGFR-2 therapy has a durable vessel fortification effect in HCC and can overcome treatment resistance to either treatment alone and increase overall survival in both anti-PD-1 therapy-resistant and anti-PD-1 therapy-responsive HCC models.
引用
- Shigeta K, Datta M, Hato T, et al. Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma. Hepatology. 2019. PMID: 31378984. doi:10.1002/hep.30889
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。